GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Selling, General, & Admin. Expense

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Selling, General, & Admin. Expense : $53.06 Mil (TTM As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Forma Therapeutics Holdings's selling, general, & admin. expense for the three months ended in Jun. 2022 was $13.94 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2022 was $53.06 Mil.


Forma Therapeutics Holdings Selling, General, & Admin. Expense Historical Data

The historical data trend for Forma Therapeutics Holdings's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Selling, General, & Admin. Expense Chart

Forma Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Selling, General, & Admin. Expense
21.54 24.40 30.78 48.33

Forma Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.47 12.75 13.24 13.14 13.94

Competitive Comparison of Forma Therapeutics Holdings's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Forma Therapeutics Holdings's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forma Therapeutics Holdings's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's Selling, General, & Admin. Expense falls into.



Forma Therapeutics Holdings Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forma Therapeutics Holdings  (NAS:FMTX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Forma Therapeutics Holdings Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Executives
Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook officer: SVP, Chief Scientific Officer
Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans director
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

Forma Therapeutics Announces Appointment of New Executive Team Members

By Business Wire Business Wire 06-30-2022

RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023